Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T-2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging
T. Chyi et C. Chang, Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T-2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging, NEUROSCIENC, 92(3), 1999, pp. 1035-1041
An appropriate detecting technique is necessary for the early detection of
neurodegenerative diseases. 3-Nitropropionic acid-intoxicated rats serve as
the animal model for one neurodegenerative disease, Huntington's disease.
Non-invasive diffusion- and T-2-weighted magnetic resonance imaging were ap
plied to study temporal evolution and spatial distribution of brain lesions
which were produced by intravenous injection of 3-nitropropionic acid in r
ats. Lesions in the striatum, hippocampus, and corpus callosum but not in t
he cortex were observed 3 and 4.5 h after 3-nitropropionic acid injection (
30 mg/kg) on the diffusion- and T2-weighted images, respectively (n = 6). T
he results demonstrated that the diffusion-weighted imaging is not only sup
erior to T-2-weighted imaging in detecting onset of 3-nitropropionic acid-i
nduced excitotoxic brain damage but also differentiates lesion and non-lesi
on areas with better spatial resolution than T2-weighted imaging. Additiona
lly, to correlate structural alterations with pathophysiological conditions
, dynamic susceptibility contrast magnetic resonance imaging was performed
before and 4 h after 3-nitropropionic acid administration (n = 8). The rela
tive cerebral blood volume was significantly elevated in the striatum (P <
0.001) but not in the cortex after 3-nitropropionic acid administration. Th
e changes in regional relative cerebral blood volume were well correlated t
o the changes in signal intensities in the corresponding areas on the diffu
sion- and T2-weighted images.
The combined structural and functional information in this study may provid
e new insights and therapeutic strategies in treating neurodegenerative dis
eases. (C) 1999 IBRO. Published by Elsevier Science Ltd.